The FDA just approved Hyrimoz, manufacturer Sandoz’s new biosimilar for the blockbuster rheumatoid arthritis drug, Humira.
This is the third Humira biosimilar to be approved by the FDA. Back in 2016, the FDA approved Amjevita, followed by Cyltezo in 2017. Unfortunately, none of these biosimilars are available in pharmacies yet, and may not be for a couple more years—likely until 2023 for Hyrimoz.
What is a biosimilar?
A biosimilar is technically the “generic” version of a biologic (a medication made from a living organism). See More